E
Elizabeth P. Harausz
Researcher at Case Western Reserve University
Publications - 14
Citations - 647
Elizabeth P. Harausz is an academic researcher from Case Western Reserve University. The author has contributed to research in topics: Tuberculosis & Delamanid. The author has an hindex of 9, co-authored 14 publications receiving 521 citations. Previous affiliations of Elizabeth P. Harausz include Henry M. Jackson Foundation for the Advancement of Military Medicine & United States Military HIV Research Program.
Papers
More filters
Journal ArticleDOI
World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
Dennis Falzon,Holger J. Schünemann,Elizabeth P. Harausz,Licé González-Angulo,Christian Lienhardt,Ernesto Jaramillo,Karin Weyer +6 more
TL;DR: The new WHO guidelines recommend a standardised 9–12 months shorter treatment regimen as first choice in patients with multidrug- or rifampicin-resistant TB (MDR/RR-TB) strains not resistant to fluoroquinolones or second-line injectable agents; resistance to these two classes of core second- line medicines is rapidly detectable with molecular diagnostics also approved by WHO in 2016.
Journal ArticleDOI
Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis.
Elizabeth P. Harausz,Elizabeth P. Harausz,Anthony J. Garcia-Prats,Stephanie Law,H. Simon Schaaf,Tamara Kredo,James A Seddon,Dick Menzies,Anna Turkova,Jay Achar,Farhana Amanullah,Pennan M. Barry,Mercedes C. Becerra,Edward D. Chan,Pei Chun Chan,D. I. Chiotan,Aldo Crossa,Peter Drobac,Lee Fairlie,Dennis Falzon,Jennifer Flood,Medea Gegia,Robert M. Hicks,Petros Isaakidis,S. M. Kadri,Beate Kampmann,Shabir A. Madhi,Else Marais,Mar'iandyshev Ao,Ana Méndez-Echevarría,Brittany K. Moore,Parpieva Nargiza,Iveta Ozere,Nesri Padayatchi,Saleem ur-Rehman,Natasha Rybak,Begoña Santiago-Garcia,N. Sarita Shah,Sangeeta Sharma,Tae Sun Shim,Alena Skrahina,Antoni Soriano-Arandes,Martin van den Boom,Marieke J. van der Werf,Tjip S. van der Werf,Bhanu Williams,Elena Yablokova,Jae-Joon Yim,Jennifer Furin,Anneke C. Hesseling +49 more
TL;DR: It is suggested that children respond favorably to MDR-TB treatment, and the use of second-line injectable agents and high-dose isoniazid were associated with treatment success, as well as the presence of severe disease on chest radiograph.
Journal ArticleDOI
New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.
Elizabeth P. Harausz,Anthony J. Garcia-Prats,James A Seddon,H. Simon Schaaf,Anneke C. Hesseling,Jay Achar,Jonathan Bernheimer,Andrea T. Cruz,Lia D'Ambrosio,Anne Detjen,Stephen M. Graham,Jennifer Hughes,Sylvie Jonckheere,Ben J. Marais,Giovanni Battista Migliori,Lindsay McKenna,Alena Skrahina,Marina Tadolini,Peyton Wilson,Jennifer Furin +19 more
TL;DR: This review fills a gap in the pediatric MDR‐TB literature by providing practice‐based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter M DR‐TB regimen in children and adolescents.
Journal ArticleDOI
QTc prolongation and treatment of multidrug-resistant tuberculosis.
Elizabeth P. Harausz,Helen Cox,Michael Rich,Carole D. Mitnick,Peter Zimetbaum,Jennifer Furin +5 more
TL;DR: What is known about QTc prolongation and the medications currently being studied or used to treat MDR-TB are discussed, and strategies for managing QTC prolongation in the context of treating such a serious infectious disease are discussed.
Journal ArticleDOI
Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.
Jennifer Furin,Emilie Alirol,Elizabeth Allen,Katherine Fielding,Corinne Merle,Ibrahim Abubakar,Janet Andersen,Geraint Davies,Keertan Dheda,Andreas H. Diacon,Kelly E. Dooley,G. Dravnice,Kathleen D. Eisenach,Daniel Everitt,D. Ferstenberg,A. Goolam-Mahomed,Martin P. Grobusch,Rajeev Gupta,Elizabeth P. Harausz,Mark Harrington,C. R. Horsburgh,Christian Lienhardt,David F. McNeeley,Carole D. Mitnick,Sharon Nachman,Payam Nahid,Andrew J. Nunn,Patrick P. J. Phillips,Carly A. Rodriguez,S. Shah,Charles D. Wells,B. Thomas-Nyang'wa,P. du Cros +32 more
TL;DR: A core set of efficacy and safety definitions as well as other important considerations in DR-TB clinical trials work are presented to ensure there is comparability in clinical trials on multidrug-resistant TB.